2015—2017年常熟市第一人民医院抗抑郁药应用分析

摘要

目的:了解常熟市第一人民医院 (以下简称"我院") 抗抑郁药的应用状况及趋势, 为临床合理用药提供参考.方法:采用回顾性方法, 参照世界卫生组织推荐的限定日剂量, 对2015—2017年我院抗抑郁药的销售金额、用药频度 (defined daily dose system, DDDs) 、限定日费用 (defined daily cost, DDC) 及其构成比、年增长率等进行统计分析.结果:2015—2017年, 我院抗抑郁药的销售金额分别为234.01万、240.27万和256.16万元, 2016年、2017年分别比上年增长2.68％和6.61％, 抗抑郁药销售金额占西药总销售金额的比例平均为0.74％.3年来, 抗抑郁药的销售金额为730.44万元, 选择性5-羟色胺再摄取抑制剂、5-羟色胺及去甲肾上腺素再摄取抑制剂的销售金额分别为549.73万、180.71万元, 其占抗抑郁药销售金额的比例分别为75.26％、24.74％;国产、合资和进口抗抑郁药的销售金额分别为339.09万、95.06万、296.29万元, 其占抗抑郁药销售金额的比例分别为46.42％、13.01％和40.56％;销售金额排序居前3位的药品依次为帕罗西汀、艾司西酞普兰和文拉法辛;DDDs排序居前3位的药品依次为帕罗西汀、文拉法辛和艾司西酞普兰;度洛西汀的DDC最大, 为16.77元.结论:抗抑郁药的使用日益增长, 新型抗抑郁药已成为临床首选, 基本符合目前的用药趋势;但应加大国产新药的开发和应用, 使用药更加安全、有效、经济.%OBJECTIVE: To investigate the application and its trend of antidepressants in Changshu No.1 People's Hospital (hereinafter referred to as "our hospital"), so as to provide references for clinical rational medication. METHODS: By reference of the defined daily dose recommended by WHO, the data of consumption sum, defined daily dose system (DDDs), defined daily cost (DDC) and its constituent ratio and annual growth rate during 2015-2017 were collected and retrospectively analyzed. RESULTS: During 2015-2017, the consumption sums of antidepressants were respectively 2.340 1 million, 2.402 7 million and 2.561 6 million yuan, with growth rates of 2.68％ in 2016 and 6.61％ in 2017, the average proportion of the consumption sum of antidepressants accounted for 0.74％ of the total consumption sum of western medicine. In the past 3 years, the total consumption sum of antidepressants were 7.304 4 million yuan, the consumption sums of selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs) were respectively 5.497 3 million and 1.807 1 million yuan, which respectively accounted for 75.26％ and 24.74％; the consumption sums of domestic, joint venture and imported antidepressants were respectively 3.390 9 million, 0.950 6 million and 2.962 9 million yuan, which respectively accounted for 46.42％, 13.01％ and 40.56％; the top 3 drugs ranked in consumption sum were paroxetine, escitalopram and venlafaxine in turn; the top 3 drugs ranked in DDDs were paroxetine, venlafaxine and escitalopram in turn; duloxetine had the largest DDC of 16.77 yuan. CONCLUSIONS: The application of antidepressants is ever-growing, and the new antidepressants have become the first clinical choice, which basically conforms to the current trend of drug application; however, the development and application of domestic new drugs should be strengthened to make the application of drugs safer, more effective and economical.